Valve replacement for appetite suppressant-induced valvular heart disease

Annals of Thoracic Surgery

Volumn 67, Issue 6, 1999, Pages 1819-1822

  Biswas, Shankha S ^a   Donovan, Carolyn L ^a   Forbess, Joseph M ^a   Royal, Stephen H ^a   Landolfo, Kevin P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; FENFLURAMINE; PHENTERMINE;

ADULT; ARTICLE; CASE REPORT; FEMALE; HEART VALVE REPLACEMENT; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; VALVULAR HEART DISEASE;

ADULT; APPETITE DEPRESSANTS; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; FENFLURAMINE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MITRAL VALVE INSUFFICIENCY; PHENTERMINE; TIME FACTORS;

EID: 0033067141     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(99)00328-8     Document Type: Article

References (19)

1. Wong J., Reddy S.S.K., Klein A.L. Anorectic drugs and valvular heart disease a biologic and clinical perspective . Cleve Clin J Med. 65:1998;35-41.
2. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine US Department of Health and Human Services interim public health recommendations, November 1997 . JAMA. 278:1997;1729-1731.
3. Connolly H.M., Crary J.L., McGoon M.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337:1997;581-588.
4. Weissman N.J., Tighe J.F. Jr, Gottdiener J.S., Gwynne J.T. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med. 339:1998;725-732.
5. Pinder R.M., Brogden R.N., Sawyer P.R., Speight T.M., Avery G.S. Fenfluramine a review of the pharmacological properties and therapeutic efficacy in obesity . Drugs. 10:1975;241-323.
6. Mitchell P., Smythe G. Hormonal responses to fenfluramine in depressed and control subjects. J Affective Disord. 19:1990;43-51.
7. Jick H., Vasilakis C., Weinrauch L.A., Meier C.R., Jick S.S., Derby L.E. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 339:1998;719-724.
8. Khan M.A., Herzog C.A., St. Peter J.V., et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 339:1998;713-718.
9. Singh J.P., Evans J.C., Levy D., et al. Prevalence of valvular regurgitation in a population-based cohort. Circulation. 96:(Suppl 1):1997;541.
10. Lebowitz N.E., Bella J.N., Roman M.J., et al. Prevalence and correlates of aortic regurgitation in American Indians the Strong Heart Study . (Abstract) J Am Soc Echocardiogr. 11:1998;559.
11. Jones E.C., Devereux R.B., Roman M.J., et al. Prevalence and correlates of mitral regurgitation in the general population the Strong Heart Study . (Abstract) J Am Soc Echocardiogr. 11:1998;500.
12. Redfield M.M., Nicholson W.J., Edwards W.D., Tajik A.J. Valve disease associated with ergot alkaloid use echocardiographic and pathologic correlations . Ann Intern Med. 117:1992;50-52.
13. Morita T., Mehendale H. Effects of chlorphenterimine and phenterimine on the pulmonary disposition of 5-hydroxytryptamine in the rat in vivo. Am Rev Respir Dis. 127:1983;747-750.
14. Thorson A.H. Endocardial sclerosis and other heart lesions in the carcinoid disease. Acta Med Scand. 334:(Suppl):1958;99-119.
15. Robiolio P.A., Rioglin V.H., Wilson J.S., et al. Carcinoid heart disease correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography . Circulation. 92:1995;790-795.
16. Robertson J.I. Serotonergic type-2 (5-HT2) antagonists a novel class of cardiovascular drugs . J Cardiovasc Pharmacol. 17:(Suppl 5):1991;S48-S53.
17. Redmon B., Raatz S., Bantle J.P. Valvular heart disease associated with fenfluramine-phentermine. (Letter) N Engl J Med. 337:1997;1773-1774.
18. Chesebro J.H., Lam J.Y., Badimon L., Fuster V. Restenosis after arterial angioplasty a hemorrheologic response to injury . Am J Cardiol. 60:1987;10B-16B.
19. Devereux R.B. Appetite suppressants and valvular heart disease. N Engl J Med. 339:1998;765-767.